Intellipharmaceutics International Inc. (NASDAQ:IPCI) announced its quarterly earnings data on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%.

Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.90 on Friday. Intellipharmaceutics International has a 12-month low of $1.41 and a 12-month high of $3.33. The company’s market capitalization is $83.37 million. The stock’s 50 day moving average price is $2.06 and its 200 day moving average price is $1.86.

Earnings History for Intellipharmaceutics International (NASDAQ:IPCI)

Several brokerages have issued reports on IPCI. Zacks Investment Research cut Intellipharmaceutics International from a “hold” rating to a “sell” rating in a research note on Thursday. Brean Capital set a $8.00 target price on Intellipharmaceutics International and gave the company a “buy” rating in a report on Monday. Finally, Maxim Group set a $6.00 target price on Intellipharmaceutics International and gave the company a “buy” rating in a report on Thursday, October 6th.

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

5 Day Chart for NASDAQ:IPCI

Receive News & Stock Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related stocks with our FREE daily email newsletter.